(Reuters) - Strong cashflows, healthy profits and low leverage remain
the norm in the sector for now but Moody's reckons the outlook
is "moderately negative", given looming threats to key patents,
likely further acquisitions and shareholder calls for buybacks.
In a new report on European pharmaceutical companies, the
agency forecasts a long-term negative bias in rating trends for
these issuers.
Read more at Reuters.com Mergers News
the norm in the sector for now but Moody's reckons the outlook
is "moderately negative", given looming threats to key patents,
likely further acquisitions and shareholder calls for buybacks.
In a new report on European pharmaceutical companies, the
agency forecasts a long-term negative bias in rating trends for
these issuers.
Read more at Reuters.com Mergers News
No comments:
Post a Comment